Ticker >

Biocon share price

Biocon Ltd.

NSE: BIOCON BSE: 532523 SECTOR: Pharmaceuticals & Drugs  225k   1k   231

368.60
0 0
BSE: 26 Jul 04:01 PM

Price Summary

Today's High

₹ 376.75

Today's Low

₹ 364.05

52 Week High

₹ 376.75

52 Week Low

₹ 217.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

44254.12 Cr.

Enterprise Value

45709.22 Cr.

No. of Shares

120.06 Cr.

P/E

370.94

P/B

4.09

Face Value

₹ 5

Div. Yield

0.14 %

Book Value (TTM)

₹  90.21

CASH

585.7 Cr.

DEBT

2040.8 Cr.

Promoter Holding

60.64 %

EPS (TTM)

₹  0.99

Sales Growth

6.74%

ROE

1.1 %

ROCE

2.77%

Profit Growth

-95.81 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Biocon Ltd.

Insugen Basalog BIOMAb EGFR CANMAb ALZUMAb KRABEVA TACROGRAF

Index Presence

The company is present in 25 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.74%
3 Year1.6%
5 Year3.56%

Profit Growth

1 Year-95.81%
3 Year-24.8%
5 Year-24.7%

ROE%

1 Year1.1%
3 Year10.83%
5 Year8.44%

ROCE %

1 Year2.77%
3 Year11.45%
5 Year9.29%

Debt/Equity

0.1884

Price to Cash Flow

-359.21

Interest Cover Ratio

1.756

CFO/PAT (5 Yr. Avg.)

0.29228769957036

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2024 60.64 0
Mar 2024 60.64 0
Dec 2023 60.64 0
Sep 2023 60.64 0
Jun 2023 60.64 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 74.837 days.
  • Company has a healthy liquidity position with current ratio of 3.9931.
  • The company has a high promoter holding of 60.64%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 44.1451080008243.

 Limitations

  • The company has shown a poor profit growth of -24.796879906375% for the Past 3 years.
  • The company has shown a poor revenue growth of 1.59951711415043% for the Past 3 years.
  • Company has negative cash flow from operations of -123.2.
  • The company is trading at a high PE of 370.94.
  • The company is trading at a high EV/EBITDA of 100.3055.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 506.7 513.2 518.7 562.8 532.6
Total Expenditure 550.7 441.2 451.5 491.5 480.4
Operating Profit -44 72 67.2 71.3 52.2
Other Income 64 36 69.6 48.5 38.9
Interest 48.1 48.3 55 56 39.5
Depreciation 29.4 29.8 30.6 30.9 29.8
Exceptional Items 1853.6 19.7 -5.2 0 0
Profit Before Tax 1796.1 49.6 46 32.9 21.8
Tax -14.7 3 11.3 8.9 7.8
Profit After Tax 1810.8 46.6 34.7 24 14
Adjusted EPS (Rs) 15.08 0.39 0.29 0.2 0.12

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1988.4 2028.4 1738.2 1992.9 2127.3
Total Expenditure 1706.5 1717.2 1677.1 1972.1 1911.6
Operating Profit 281.9 311.2 61.1 20.8 215.7
Other Income 205.8 151.5 187.2 274.1 240
Interest 1.2 0.4 0.4 69.6 198.8
Depreciation 98 103.5 108.2 116.9 121.1
Exceptional Items 159.7 0 0 2862.8 14.5
Profit Before Tax 548.2 358.8 139.7 2971.2 150.3
Tax 111.9 78.3 53.6 122.8 31
Net Profit 440.9 280.5 86.1 2848.4 119.3
Adjusted EPS (Rs.) 3.64 2.34 0.72 23.72 0.99

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 600 600 600.3 600.3 600.3
Total Reserves 6937.3 7307.1 7492.6 10315.7 10312
Borrowings 0.7 0 75.9 1297.7 2040.8
Other N/C liabilities -134.7 -30 -10.7 95.4 116.5
Current liabilities 728 550.2 590.9 698 691.2
Total Liabilities 8131.3 8427.3 8749 13007.1 13760.8
Assets
Net Block 720.7 728.6 804.7 899.4 900.4
Capital WIP 151.9 164.6 270.3 328.9 545
Intangible WIP 0 14.6 14.6 14.6 14.6
Investments 4814 5073.4 5017.8 8949.8 9255.6
Loans & Advances 280.9 150.5 154.2 159 204.1
Other N/C Assets 80.1 126.3 85.2 89.4 81.1
Current Assets 2083.7 2169.3 2402.2 2566 2760
Total Assets 8131.3 8427.3 8749 13007.1 13760.8
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 559.9 358.8 139.7 2971.2 150.3
Adjustment -68.1 117.8 108.3 -2726.9 112.3
Changes in Assets & Liabilities -14 156 -172 16.1 -358.3
Tax Paid -90.7 -61.3 -28.4 -41.1 -27.5
Operating Cash Flow 387.1 571.3 47.6 219.3 -123.2
Investing Cash Flow -188.9 -720.6 -302.1 -1173.1 -294.7
Financing Cash Flow -128.9 27.8 112 1039.4 343.6
Net Cash Flow 69.3 -121.5 -142.5 85.6 -74.3

Corporate Actions

Investors Details

PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
promoters 60.64 60.64 60.64 60.64 60.64
dev mazumdar 0.08 0.08 0.08 0.08 0.08
glentec international 19.76 19.76 19.76 19.76 19.76
kiran mazumdar shaw 39.66 40.36 40.36 40.36 40.36
ravi rasendra mazumdar 0.44 0.44 0.44 0.44 0.44
j m m shaw 0.70 - - - -
PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
investors 39.36 39.36 39.36 39.36 39.36
arun suresh chandavarkar 1.10 1.10 1.10 1.10 1.10
beneficial holdings under... 0.46 0.46 0.46 0.46 0.46
investor education and pr... 0.01 0.01 0.01 0.01 0.01
kotak equity opportunitie... - - - - 1.55
lici child fortune plus g... - - - 4.41 4.94
sbi contra fund - - - 2.74 2.72
quant mutual fund - quant... - - - 1.24 -
icici prudential equity a... - 1.22 1.99 - -
lici ulip-growth fund 4.41 4.41 4.41 - -
mirae asset large cap fun... - 1.81 1.50 - -
sbi healthcare opportunit... - 1.79 2.86 - -
aditya birla sun life tru... 1.43 - - - -
icici prudential midcap 1... 1.26 - - - -
mirae asset balanced adva... 2.11 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Biocon’s arm gets EMA’s nod to manufacture biosimilar Bevacizumab at Bengaluru facility24 Jun 2024, 4:58PM USFDA concludes GMP inspection of Biocon’s API facility in Visakhapatnam24 Jun 2024, 4:41PM Biocon informs about company statement24 Jun 2024, 9:46AM Biocon informs about updates15 Jun 2024, 2:37PM Biocon informs about analyst meet 6 Jun 2024, 5:18PM Biocon gets nod for Micafungin from USFDA4 Jun 2024, 9:28AM Biocon informs about press release24 May 2024, 10:03AM Biocon signs exclusive licensing, supply agreement with Handok24 May 2024, 9:22AM Biocon’s arm gets USFDA’s nod for Yesafili21 May 2024, 9:30AM Biocon informs about press release21 May 2024, 9:18AM Biocon reports 46% fall in Q4 consolidated net profit17 May 2024, 11:43AM Biocon - Quaterly Results16 May 2024, 5:16PM Biocon - Quaterly Results16 May 2024, 5:16PM Biocon - Quaterly Results16 May 2024, 5:16PM Biocon informs about press release13 May 2024, 9:50AM Biocon signs exclusive distribution, supply agreement with Medix13 May 2024, 9:25AM Biocon informs about disclosure29 Apr 2024, 5:38PM Biocon informs about disclosure 20 Apr 2024, 2:30PM Biocon signs licensing and supply agreement with Biomm S.A.18 Apr 2024, 9:17AM Biocon’s arm transfers branded formulations business in India to Eris Lifesciences3 Apr 2024, 11:17AM Biocon informs about notification1 Apr 2024, 10:06AM Biocon informs about trading window closure28 Mar 2024, 5:20PM Biocon gets approval from MHRA, UK for complex formulation Liraglutide 28 Mar 2024, 9:39AM Biocon informs about newspaper advertisement23 Mar 2024, 9:33AM Biocon informs about loss of share certificate 16 Mar 2024, 2:38PM Biocon’s arm enters into long-term commercial collaboration with Eris Lifesciences15 Mar 2024, 2:09PM Biocon informs about disclosure 14 Mar 2024, 4:40PM Biocon informs about company statement4 Mar 2024, 9:55AM USFDA concludes inspection at Biocon Campus Site 1 facility of Biocon’s arm1 Mar 2024, 9:53AM Biocon informs about disclosure29 Feb 2024, 5:13PM Biocon informs about analyst meet 27 Feb 2024, 11:33AM Biocon gets penalty of Rs 3.04 crore over GST-related issues24 Feb 2024, 2:43PM Biocon informs about analyst meet20 Feb 2024, 2:15PM Biocon included in S&P Global Sustainability Yearbook 2024 20 Feb 2024, 12:30PM Biocon reports consolidated net profit of Rs 753 crore in Q39 Feb 2024, 2:47PM Biocon informs about press release9 Feb 2024, 2:18PM Biocon informs about press release9 Feb 2024, 11:51AM Biocon’s arm enters into partnership with Sandoz 9 Feb 2024, 9:22AM Biocon - Quaterly Results8 Feb 2024, 7:08PM Biocon - Quaterly Results8 Feb 2024, 7:08PM Biocon gets tentative approval from USFDA for Dasatinib tablets 7 Feb 2024, 10:59AM Biocon informs about closure of trading window29 Dec 2023, 4:33PM Biocon’s arm inks pact with Sandoz 26 Dec 2023, 11:59AM Biocon informs about disclosure20 Dec 2023, 2:21PM Biocon informs about press release18 Dec 2023, 5:06PM Biocon’s arm acquires biosimilars business in around 120 countries18 Dec 2023, 4:45PM Biocon informs about press release15 Dec 2023, 3:24PM Biocon’s associate company completes $165 million Series C financing13 Dec 2023, 5:20PM Biocon’s arm completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe30 Nov 2023, 4:48PM Biocon - Quaterly Results10 Nov 2023, 4:24PM

Biocon Stock Price Analysis and Quick Research Report. Is Biocon an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Biocon and its performance over the period of time. Biocon stock price today is Rs 368.5.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Biocon cash from the operating activity was Rs -123.2 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Biocon has a Debt to Equity ratio of 0.1884 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Biocon , the EPS growth was -95.8116 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Biocon has OPM of 10.1396135946975 % which is a bad sign for profitability.
     
  • ROE: Biocon have a poor ROE of 1.1027 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Biocon is Rs 368.5. One can use valuation calculators of ticker to know if Biocon share price is undervalued or overvalued.
Last Updated on:
Brief about Biocon

Biocon Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Biocon Ltd. is a leading biopharmaceutical company in India that specializes in the development and manufacturing of biosimilars, novel biologics, and complex small molecules.  We will provide a comprehensive stock analysis of Biocon Ltd. for long-term stock investors.

Biocon Ltd. Share Price 

Biocon's share price has been performing well in recent years, with a steady growth trend. The company's share price is influenced by various factors such as market conditions, industry trends, and company-specific news. Ticker pre-built screening tools can help you keep track of Biocon's share price and compare it with its peers.

Biocon Ltd. Balance Sheet 

Biocon's balance sheet provides insights into the company's financial health and its ability to meet its financial obligations. Our premium features, such as DCF Analysis, BVPS Analysis, and DuPont analysis, can help you calculate the fair value of Biocon's stock based on its balance sheet. By analyzing the company's assets, liabilities, and equity, you can gain a better understanding of its financial position and make informed investment decisions.

Biocon Ltd. Annual Report 

Biocon's annual report provides a comprehensive overview of the company's financial performance, business strategy, and future outlook. You can download Biocon's annual reports from Ticker and analyze them to gain insights into the company's operations and growth prospects. 

Biocon Ltd. Dividend 

Biocon has a consistent track record of paying dividends to its shareholders. The company's dividend payout ratio and yield can provide insights into its financial health and growth prospects. By analyzing Biocon's dividend history and payout policies, you can make informed decisions about investing in the company's stock.

Biocon Ltd. Quarterly Results 

Biocon's quarterly results provide insights into its financial performance and growth prospects. Our premium features, such as earnings multiple approach and DuPont analysis, can help you analyze Biocon's quarterly results and calculate its fair value. By comparing Biocon's quarterly results with its peers and tracking its progress over time, you can make informed investment decisions.

Biocon Ltd. Stock Price 

Biocon's stock price is influenced by various factors such as market conditions, industry trends, and company-specific news. Our pre-built screening tools can help you keep track of Biocon's stock price and compare it with its peers. By analyzing Biocon's stock price trends and market conditions, you can make informed investment decisions.

Biocon Ltd. Price Chart 

Biocon's price chart provides a visual representation of its stock price trends over time. You can use our pre-built screening tools to analyze Biocon's price chart and compare it with its peers. By analyzing Biocon's price chart, you can gain insights into its stock price trends and make informed investment decisions.

Biocon Ltd. News 

Biocon's news provides insights into its business operations, growth prospects, and industry trends. You can use our pre-built screening tools to keep track of Biocon's news and analyze its impact on the company's stock price. By staying up-to-date with Biocon's news, you can make informed investment decisions.

Biocon Ltd. Concall Transcripts 

Biocon's concall transcripts provide insights into its management's views on the company's financial performance, business strategy, and future outlook. You can download Biocon's concall transcripts from Ticker and analyze them to gain insights into the company's operations and growth prospects. By analyzing Biocon's concall transcripts, you can make informed investment decisions.

Biocon Ltd. Investor Presentations 

Biocon's investor presentations provide insights into its business operations, growth prospects, and industry trends. You can download Biocon's investor presentations from Ticker and analyze them to gain insights into the company's operations and growth prospects. By staying up-to-date with Biocon's investor presentations, you can make informed investment decisions.

Biocon Ltd. Promoters 

Biocon's promoters are highly experienced professionals with a proven track record in the biopharmaceutical industry. By analyzing Biocon's promoters and their past performance, you can gain insights into the company's business operations and growth prospects. 

Biocon Ltd. Shareholders 

Biocon's shareholders are a diverse group of investors with different investment objectives and risk profiles. By analyzing Biocon's shareholders and their investment patterns, you can gain insights into the company's stock price trends and growth prospects.Ticker pre-built screening tools can help you compare Biocon's shareholders with its peers and track their progress over time.

Biocon Ltd. ROCE

The Return on Capital Employed (ROCE) is a fundamental financial ratio that measures a company's profitability and efficiency in utilizing its capital. Biocon Ltd.'s ROCE indicates how well the company generates profits from the capital employed in its operations. This ratio is obtained by dividing the company's operating profit by its capital employed. To view Biocon Ltd.'s ROCE data, refer to the financials table or ratio section on this page.

Biocon Ltd. EBITDA

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. Biocon Ltd.'s EBITDA reflects its operating performance by excluding non-operating expenses. EBITDA is a useful metric for comparing companies' profitability and efficiency. To access Biocon Ltd.'s EBITDA data, refer to the financials table or ratio section provided on this page.

Biocon Ltd. DPS

DPS refers to Dividends Per Share, which indicates the amount of money paid to shareholders for each share owned. Biocon Ltd.'s DPS measures the company's willingness and ability to distribute profits to its shareholders. Investors often consider DPS when evaluating the income potential of a stock. To find Biocon Ltd.'s DPS data, refer to the financials table or ratio section featured on this page.

Biocon Ltd. EPS

EPS, or Earnings Per Share, is a financial metric that shows the profitability of a company on a per-share basis. Biocon Ltd.'s EPS reveals the portion of its profit allocated to each outstanding share. This ratio is significant for investors as it helps determine the value of a stock and its potential for growth. To access Biocon Ltd.'s EPS data, refer to the financials table or ratio section provided above.

Read More
X